Complete Omics published novel technologies on SCIENCE and SCIENCE IMMUNOLOGY.
To identify truly personalized cancer therapeutic target is the 1st step of the personalized cancer therapeutics. Complete Omics’ Multi-Omics molecular diagnostic pipeline has achieved two extraordinary achievements in this new incoming era, and we are dedicated to develop more advanced multi-omics molecular diagnostic technologies and will focus on taking them to rapid commercialization.
Congratulations to our lab alumni founders in Thrive Earlier Detection.
NEW YORK – Exact Sciences has entered into a definitive agreement to acquire liquid biopsy test developer Thrive Earlier Detection for cash and stock consideration of up to $2.15 billion.
MANA-SRM pipeline and its application in personalized cancer therapeutics.
SAFE-SRM is the 1st pipeline built for clinical proteomics-based cancer diagnostics. It established a pipeline for cancer diagnostics through monitoring proteomic biomarkers, and for high throughput validation of potential biomarkers.
SAFE-SRM, 1st pipeline for clinical proteomics
SAFE-SRM is the 1st pipeline built for clinical proteomics-based cancer diagnostics. It established a pipeline for cancer diagnostics through monitoring proteomic biomarkers, and for high throughput validation of potential biomarkers.
MT-SRM, direct detection of mutant proteins as cancer-specific biomarkers
SAFE-SRM is the 1st pipeline built for clinical proteomics-based cancer diagnostics. It established a pipeline for cancer diagnostics through monitoring proteomic biomarkers, and for high throughput validation of potential biomarkers.